TuHURA Biosciences Inc (NASDAQ:HURA) — Market Cap & Net Worth
Market Cap & Net Worth: TuHURA Biosciences Inc (HURA)
TuHURA Biosciences Inc (NASDAQ:HURA) has a market capitalization of $128.09 Million ($128.09 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18354 globally and #4286 in its home market, demonstrating a 3.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TuHURA Biosciences Inc's stock price $2.09 by its total outstanding shares 63726617 (63.73 Million). Also see balance sheet size of TuHURA Biosciences Inc for a full breakdown of the balance sheet.
TuHURA Biosciences Inc Market Cap History: 2015 to 2026
TuHURA Biosciences Inc's market capitalization history from 2015 to 2026. Data shows change from $1.05 Trillion to $133.19 Million (-55.52% CAGR). Also see cash efficiency ratio of TuHURA Biosciences Inc for how efficiently the company converts equity into cash flow.
Index Memberships
TuHURA Biosciences Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #511 of 976 |
Weight: TuHURA Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TuHURA Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TuHURA Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check TuHURA Biosciences Inc (HURA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HURA by Market Capitalization
Companies near TuHURA Biosciences Inc in the global market cap rankings as of September 18, 2026. Review HURA intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to TuHURA Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
TuHURA Biosciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, TuHURA Biosciences Inc's market cap moved from $1.05 Trillion to $ 133.19 Million, with a yearly change of -55.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $133.19 Million | +176.20% |
| 2025 | $48.22 Million | -81.50% |
| 2024 | $260.64 Million | -31.26% |
| 2023 | $379.17 Million | -97.53% |
| 2022 | $15.37 Billion | -72.98% |
| 2021 | $56.88 Billion | -60.16% |
| 2020 | $142.75 Billion | +85.51% |
| 2019 | $76.95 Billion | -79.82% |
| 2018 | $381.40 Billion | -68.62% |
| 2017 | $1.22 Trillion | -65.82% |
| 2016 | $3.56 Trillion | +239.26% |
| 2015 | $1.05 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of TuHURA Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $128.09 Million USD |
| MoneyControl | $128.09 Million USD |
| MarketWatch | $128.09 Million USD |
| marketcap.company | $128.09 Million USD |
| Reuters | $128.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more